Sponsored Post: Addex Therapeutics Ltd reportedly escalated in pre-market trading after it disclosed that its partner Janssen Pharmaceuticals, Inc said to have received FDA’s Investigational New Drug approval to start a Phase 2a clinical study in epilepsy. Check disclaimer in the landing page. Apparently, these other companies could be promoting the adoption of electronic health records globally. To get fast tracking updates on their latest healthcare innovations, read further: https://b.link/PotentialBillionWorthDataSecurity
Learn What Undervalued Company Potentially Could Be Well Positioned In The Electronic Health Data Security Sector
Learn What Undervalued Company Potentially Could Be Well Positioned In The Electronic Health Data Security Sector
b.link
M
Addex ADX71149 Receives IND Approval to Start a Phase 2a Clinical Study in Epilepsy Thu Jan 21 07:02:03 2021 EDT First patient treated with ADX71149 (JNJ-40411813) scheduled for Q2 2021 Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that its partner Janssen Pharmaceuticals, Inc. , part of the Janssen Pharmaceutical Companies of Johnson & Johnson , has received FDA’s Investigational New Drug (IND) approval to begin a Phase 2a proof of concept study with the selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulator (PAM), JNJ-40411813 (ADX71149), in patients with epilepsy. The first patient is expected to be treated during Q2 2021.
Pre Market Resistance at 18.20 - then there is little resistance upwards.
s
ADXN exploded and I missed out because I wasn’t listening to the great folks over at (http://Stocks-tracker.com). The next big winner won’t miss me. Don’t let it miss you either. Join them now
P
Here is another dirt cheap LOW FLOAT Bomb which awaiting FDA approval =1000% UPSIDE
(HSDT) Market Cap $24 mil / Shares Out 1.4 mil / FDA APPROVAL for Multiple Sclerosis Product IMMINENT / UNKNOWN stock =PICK OF THE CENTURY potential 10+ BAGGERRRR guys
K
3 o’clock sour hour. Can it fill the gap?
Bearish
T
What part of the game is this? Got in at $15.50 and thought I was doing something. Feels like it’s being held down. Might have to wait for AH
K
I’m pretty sure Darmesh shorted this when he told his minions to buy this morning
Bearish
m
Pre-market was $18.08 so buying anything below is a bonus
Bullish
C
ADXN premarket was $28
S
$ADXN ADXN.S.W TICKER CHF SWISS THIS IS THERE PHARMACEUTICAL STOCK ITS ROCKETING TODAY thats the ticker its there pharmaceutical side look at it already jumped 20%
T
Well the next time this goes to $17 is when Phase 3 is done.
H
This company partnered years back with J and J and actually have very different pipeline. Suppose to be a read out soon.
P
Seems like a good buy now after the recent drop due to the offering. Addex has a deep pipeline and now more $ (or actually CHF) to advance it.
Bullish
S
They have a breakthrough on parkinsonism disease trial is January 2021
K
Was up 120% now 20%. That’s pretty bearish. Definitely going red tomorrow
Bearish
H
What moving this today? Was going to add to this but had it for the last few years in foreign shares.
K
Stick a fork in it and don’t ever listen to Darmesh on Discord or ST. Gut is a major piece of brown stuff
Bearish
S
This is going to rock today
K
I guess Darmesh even called it quits. Don’t see him on ST anymore hyping this.
Bearish
B
SNPX= ALZHEIMER PHASE 2b for 8 mil valuation =LIFETIME OPP !!! LOAD UP
(SNPX) MCap 8 million trading UNDER Cash --Shares Out 5 millon --ALZHEIMER PHASE 2b data soon /NEW listed stock = PICK OF THE CENTURY ...2000%+++ and more UPSIDE on this low float sleeping giant .GLTA
Addex Therapeutics Ltd reportedly escalated in pre-market trading after it disclosed that its partner Janssen Pharmaceuticals, Inc said to have received FDA’s Investigational New Drug approval to start a Phase 2a clinical study in epilepsy. Check disclaimer in the landing page. Apparently, these other companies could be promoting the adoption of electronic health records globally. To get fast tracking updates on their latest healthcare innovations, read further: https://b.link/PotentialBillionWorthDataSecurity
Thu Jan 21 07:02:03 2021 EDT
First patient treated with ADX71149 (JNJ-40411813) scheduled for Q2 2021
Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that its partner Janssen Pharmaceuticals, Inc. , part of the Janssen Pharmaceutical Companies of Johnson & Johnson , has received FDA’s Investigational New Drug (IND) approval to begin a Phase 2a proof of concept study with the selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulator (PAM), JNJ-40411813 (ADX71149), in patients with epilepsy. The first patient is expected to be treated during Q2 2021.
Pre Market Resistance at 18.20 - then there is little resistance upwards.
(HSDT) Market Cap $24 mil / Shares Out 1.4 mil / FDA APPROVAL for Multiple Sclerosis Product IMMINENT / UNKNOWN stock =PICK OF THE CENTURY potential 10+ BAGGERRRR guys
(SNPX) MCap 8 million trading UNDER Cash --Shares Out 5 millon --ALZHEIMER PHASE 2b data soon /NEW listed stock = PICK OF THE CENTURY ...2000%+++ and more UPSIDE on this low float sleeping giant .GLTA